Cargando…
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
Antibody-based PD-1/PD-L1 blockade therapies have taken center stage in immunotherapies for cancer, with multiple clinical successes. PD-1 signaling plays pivotal roles in tumor-driven T-cell dysfunction. In contrast to prior approaches to generate or boost tumor-specific T-cell responses, antibody-...
Autores principales: | Tan, Shuguang, Chen, Danqing, Liu, Kefang, He, Mengnan, Song, Hao, Shi, Yi, Liu, Jun, Zhang, Catherine W.-H., Qi, Jianxun, Yan, Jinghua, Gao, Shan, Gao, George F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5205664/ https://www.ncbi.nlm.nih.gov/pubmed/27815822 http://dx.doi.org/10.1007/s13238-016-0337-7 |
Ejemplares similares
-
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
por: Tan, Shuguang, et al.
Publicado: (2017) -
The FG Loop of PD-1 Serves as a “Hotspot” for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy
por: Chen, Danqing, et al.
Publicado: (2019) -
Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016) -
PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy
por: Lu, Dan, et al.
Publicado: (2022) -
Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy
por: Liu, Hongchuan, et al.
Publicado: (2020)